Session 9: Immunology & Immunotherapy

Chair(s)

• 

  Nadia Hindi, MD

  Medical Oncologist
  Fundacion Jimenez Diaz University Hospital/HG Villalba and Instituto de Investigaciones Sanitarias Fundación Jimenez Diaz
  Madrid, Madrid, Spain

Moderator(s)

• 

  Neeta Somaiah, MD

  Associate Professor
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• AI

  Antoine Italiano, N/A, MD, PhD

  Institut Bergonié
  Bordeaux, Aquitaine, France
• 

  John Mullinax, MD

  Assistant Member, Sarcoma Department, Immunology Department Surgical Director, Cellular Immunotherapy Program
  Moffitt Cancer Center
  Tampa, Florida, United States

Presentations:

• 3:30 PM – 3:38 PM

  A MULTI-OMICS APPROACH TO EXPLORE THE PROGNOSTIC IMPACT OF CANCER IMMUNITY IN CHORDOMAS
  

  Author: Siddh van Oost, MSc – Department of Pathology / Leiden Centre for Computational Oncology, Leiden University Medical Center

  Co-Author: Debora Meijer, MSc – Department of Pathology / Leiden Centre for Computational Oncology, Leiden University Medical Center

  Co-Author: Brendy E. van Den Akker, N/A, BSc – LUMC

  Co-Author: Ruud Van Der Breggen, BSc – Department of Pathology, LUMC

  Co-Author: Inge H. Braire-deBruijn, N/A, MD – Department of Pathology, Leiden University Medical Center, Leiden

  Co-Author: Marieke Ijsselsteijn, MSc – Department of Pathology, LUMC

  Co-Author: Wilco Peul, Professor, MD – University Neurosurgical Centre Holland, LUMC

  Co-Author: Robert Van der Wal, MD, PhD (he/him/his) – Leiden University Medical center

  Co-Author: Manon van der ploeg, BSc – Department of Pathology, LUMC

  Co-Author: Samuel Polak, MD – University Neurosurgical Centre Holland, LUMC

  Co-Author: Jessica Roelands, PhD – Department of Pathology, LUMC

  Co-Author: Pauline Wijers-Koster, BSc – Department of Pathology, LUMC

  Co-Author: Noel de Miranda, PhD – Department of Pathology / Leiden Centre for Computational Oncology, Leiden University Medical Center

  Co-Author: J.V.M.G. Bovee, MD, PhD – Department of Pathology, Leiden University Medical Center
• 3:38 PM – 3:46 PM

  INTRATUMORAL INT230-6 (CISPLATIN, VINBLASTINE, SHAO) ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE SAFETY IN ADULTS WITH REFRACTORY SARCOMAS (NCT 03058289)
  

  Author: Matthew A. Ingham, MD – New York Presbyterian Hospital/Columbia University Medical Center

  Co-Author: James S. Hu, MD – University of Southern California Norris Comprehensive Cancer Center

  Co-Author: Giles Francis Whalen, MD – University of Massachusetts Memorial Medical Center,

  Co-Author: Jacob Thomas, MD – University of Southern California Norris Comprehensive Cancer Center

  Co-Author: Anthony B. El-Khoueiry, N/A, MD – University of Southern California Norris Comprehensive Cancer Center

  Co-Author: Diana Hanna, MD – USC Norris Comprehensive Cancer Center

  Co-Author: Anthony Olszanski, MD – Johns Hopkins Sidney Kimmel Cancer Center

  Co-Author: Christian F. Meyer, MD, PhD – Johns Hopkins Sidney Kimmel Cancer Center

  Co-Author: Nilofer S. Azad, MD – Johns Hopkins Sidney Kimmel Cancer Center

  Co-Author: Luis Camacho, MD – Center for Oncology and Blood Disorders

  Co-Author: Lewis Bender, MS (he/him/his) – Intensity Therapeutics

  Co-Author: Lillian L. Siu, MD – Princess Margaret Cancer Centre, University Health Network

  Co-Author: Albiruni Ryan Abdul Razak, MB, MRCPI (he/him/his) – Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; Department of Medical Oncology, Mount Sinai Hospital

  Co-Author: Ian B. Walters, MD – Intensity Therapeutics
• 3:46 PM – 3:54 PM

  STING ACTIVATION AS AN IMMUNOGENIC THERAPY FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
  

  Author: Karys Hildebrand, BScH – University of Calgary

  Co-Author: Kurt N. Hildebrand, BScH (he/him/his) – University of Calgary

  Co-Author: Kayla Marritt, N/A, n/a – University of Calgary

  Co-Author: Carolina Salazar Arcila, MSc – University of Calgary

  Co-Author: Michael Monument, N/A, MD, MSc, FRCSC – University of Calgary McCaig Bone and Joint Institute
• 3:54 PM – 4:02 PM

  HIGH-THROUGHPUT DRUG SCREENING IDENTIFIES GSK3B INHIBITION AS A THERAPEUTIC TARGET TO ENHANCE ALLOGENEIC NK CELL CYTOTOXICITY IN EWING SARCOMA
  

  Co-Author: Naoki Oike, MD (he/him/his) – Niigata University

  Co-Author: Ryota Shirai, MD, PhD – Department of Pediatrics, University of Colorado

  Co-Author: Taylor Gillis, BS – School of Medicine, University of Nevada Las Vegas

  Co-Author: Deandra Walker, MS, CVT (she/her/hers) – Department of Pediatrics, University of Colorado

  Co-Author: Avery Bodlak, BS – Department of Pediatrics, University of Colorado

  Co-Author: Timothy Porfilio, BS – Department of Pediatrics, University of Colorado

  Co-Author: Michael Verneris, MD – Department of Pediatrics, University of Colorado

  Author: Masanori Hayashi, MD – Department of Pediatrics, University of Colorado
• 4:02 PM – 4:15 PM

  Q&A
• 4:15 PM – 4:23 PM

  A PHASE IA/IB STUDY OF BOTENSILIMAB, A NOVEL INNATE/ADAPTIVE IMMUNE ACTIVATOR, PLUS BALSTILIMAB FOR THE TREATMENT OF PATIENTS WITH SARCOMA
  

  Author: Breelyn A. Wilky, MD (she/her/hers) – University of Colorado

  Co-Author: Justin C. Moser, N/A, MD – HonorHealth Research and Innovation Institute

  Co-Author: Michael S. Gordon, MD (he/him/his) – HonorHealth Research Institute

  Co-Author: Leah Anton, N/A, NP, MSN – Sylvester Comprehensive Cancer Center, University of Miami

  Co-Author: Marwan G. Fakih, N/A, MD – City of Hope Comprehensive Cancer Center

  Co-Author: Mark Agulnik, MD – City of Hope Comprehensive Cancer Center

  Co-Author: Andrea Bullock, N/A, MD – Beth Israel Deaconess Medical Center

  Co-Author: J. Luke Godwin, N/A, MD – Agenus

  Co-Author: Jaymin M. Patel, MD

  Co-Author: Joseph E. Grossman, N/A, MD – Agenus

  Co-Author: Waldo Ortuzar Feliu, N/A, MD – Agenus

  Co-Author: Katherine Rosenthal, RN, MSN, OCN, CCRP (she/her/hers) – Agenus

  Co-Author: Bhupendra Rawal, N/A, MS – Agenus

  Co-Author: Bonnie L. Bullock, PhD (she/her/hers) – Agenus

  Co-Author: Hunter Cole, N/A, MPH – Agenus

  Co-Author: Steven J. O'Day, MD (he/him/his) – Agenus

  Co-Author: Anthony B. El-Khoueiry, N/A, MD – University of Southern California Norris Comprehensive Cancer Center

  Co-Author: Gary K. Schwartz, MD – Columbia University Herbert Irving Comprehensive Cancer Center

  Co-Author: Apostolia M. Tsimberidou, N/A, MD, PhD – The University of Texas MD Anderson Cancer Center

  Co-Author: Jonathan C. Trent, MD, PhD – University of Miami/Sylvester Comprehensive Cancer Center
• 4:23 PM – 4:31 PM

  COMBINATION OF ONCOLYTIC VIROTHERAPY WITH ISOLATED LIMB PERFUSION IN ADVANCED UNRESECTABLE EXTREMITY SARCOMA RESULTS IN IMMUNE ACTIVATION: RESULTS OF A PHASE I/II CLINICAL TRIAL
  

  Author: Andrew J. Hayes, MD PhD – Royal Marsden Hospital

  Co-Author: Emma Davies, MD – Institute of Cancer Research

  Co-Author: Henry Smith, MD PhD – Institute of Cancer Research

  Co-Author: Pablo Nenclares, MD (he/him/his) – Institute of Cancer Research

  Co-Author: David Mansfield, PhD – Institute of Cancer Research

  Co-Author: Victoria Roulstone, PhD – Institute of Cancer Research

  Co-Author: Joan Kyula-Currie, PhD – Institute of Cancer Research

  Co-Author: Antonio Rullan, MD – Institute of Cancer Research

  Co-Author: Emmanuel Patin, PhD – Institute of Cancer Research

  Co-Author: Malin Pedersen, PhD – Institute of Cancer Research

  Co-Author: Kabir Mohammed, N/A, n/a – The Royal Marsden NHS Foundation Trust

  Co-Author: Myles JF Smith, MB BCh BAO, PhD, FRCSI, FRCS – Sarcoma Unit, Royal Marsden Hospital

  Co-Author: Andrew Furness, MD PhD – Royal Marsden Hopsital

  Co-Author: Robin L. Jones, N/A, MD, PhD – The Royal Marsden NHS Foundation Trust

  Co-Author: Alan Melcher, MD PhD – Institute of Cancer Research

  Co-Author: Kevin Harrington, MD PhD – Institute of Cancer Research
• 4:31 PM – 4:39 PM

  REAL-WORLD EXPERIENCE OF THE EFFICACY, TOLERABILITY, AND PREDICTORS OF RESPONSE TO IPILIMUMAB PLUS NIVOLUMAB IN ADVANCED NON-TRANSLOCATED SARCOMAS
  

  Author: Samantha Armstrong, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Lauren Blackwell, PharmD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Korbin Davis, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Jason Childress, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Taylor Stethen, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Paul Niziolek, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Mark Tann, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Sarah Spargo, PharmD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Pauline Kim, PharmD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Allie Carter, MS – Indiana University Department of Biostatistics and Health Data Science

  Co-Author: Lawrence Wurtz, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Christopher Collier, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Anna Roshal, MD – Indiana University Melvin and Bren Simon Cancer Center

  Co-Author: Susan Perkins, PhD – Indiana University Department of Biostatistics and Health Data Science

  Co-Author: Daniel Rushing, MD (he/him/his) – Indiana University Melvin and Bren Simon Cancer Center
• 4:39 PM – 4:47 PM

  FINAL ANALYSIS FROM SPEARHEAD-1 COHORT 1 OF AFAMITRESGENE AUTOLEUCEL (“AFAMI-CEL” [FORMERLY ADP-A2M4]) IN ADVANCED SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA
  

  Author: Brian A. Van Tine, MD, PhD – Washington University School of Medicine

  Co-Author: Dejka M. M. Araujo, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Jean-Yves Blay, MD, PhD (he/him/his) – Centre Léon Bérard and Université Claude Bernard, Lyon, France

  Co-Author: Axel Le Cesne, MD – Department of Medicine, Gustave Roussy

  Co-Author: Kristen N. Ganjoo, MD – Stanford Cancer Center, Stanford University

  Co-Author: Claudia Maria Valverde Morales, MD (she/her/hers) – Vall D'Hebron University Hospital

  Co-Author: Albiruni Ryan Abdul Razak, MB, MRCPI (he/him/his) – Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; Department of Medical Oncology, Mount Sinai Hospital

  Co-Author: Scott M. Schuetze, MD, PhD (he/him/his) – University of Michigan

  Co-Author: Edward Y. Kim, MD (he/him/his) – University of Washington/Fred Hutch Cancer Center

  Co-Author: Erin Van Winkle, BS – Adaptimmune

  Co-Author: Cheryl McAlpine, PhD – Adaptimmune

  Co-Author: Jean-Marc Navenot, PhD – Adaptimmune

  Co-Author: Martin Isabelle, PhD – Adaptimmune

  Co-Author: Robyn Broad, PhD – Adaptimmune

  Co-Author: Revashnee Naidoo, MRes – Adaptimmune

  Co-Author: Ruoxi Wang, PhD – Adaptimmune

  Co-Author: Dzmitry G. Batrakou, PhD (he/him/his) – Adaptimmune

  Co-Author: Thejo Annareddy, MS – Adaptimmune

  Co-Author: Swethajit Biswas, MB, ChB (Hons), MRCP (UK), DPhil (Oxon) – Adaptimmune

  Co-Author: Dennis Williams, PharmD – Adaptimmune

  Co-Author: Elliot Norry, MD – Adaptimmune

  Co-Author: Sandra P. D'Angelo, MD – Memorial Sloan Kettering Cancer Center
• 4:47 PM – 5:00 PM

  Q&A